Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Serological Response in Lung Transplant Recipients after Two Doses of SARS-CoV-2 mRNA Vaccines

Madhusudhanan Narasimhan, Lenin Mahimainathan, Andrew E. Clark, Amena Usmani, Jing Cao, Ellen Araj, Fernando Torres, Ravi Sarode, Vaidehi Kaza, Chantale Lacelle, Alagarraju Muthukumar
doi: https://doi.org/10.1101/2021.04.26.21255926
Madhusudhanan Narasimhan
1Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lenin Mahimainathan
1Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew E. Clark
1Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amena Usmani
1Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jing Cao
1Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ellen Araj
1Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fernando Torres
2Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ravi Sarode
1Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas
2Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vaidehi Kaza
2Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chantale Lacelle
1Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: alagarraju.muthukumar@utsouthwestern.edu chantale.lacelle@utsouthwestern.edu
Alagarraju Muthukumar
1Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: alagarraju.muthukumar@utsouthwestern.edu chantale.lacelle@utsouthwestern.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

The immunological effectiveness of SARS-CoV-2 mRNA vaccines in lung transplant (LT) recipients is largely unknown. Thus, we assessed the effect of Pfizer-BioNTech and Moderna mRNA vaccines’ two-dose (2D) regimen on humoral responses in immunocompromised lung transplant (LT) recipients. About 25% (18/73) of SARS-CoV-2 uninfected-LT patients generated positive spike-IgG response following 2D of vaccines, with 36% (9/25) in the Moderna cohort and only 19% (9/48) in the Pfizer cohort. 2D in LT patients elicited significantly lesser median IgGSP response (1.7 AU/mL, 95% CI: 0.6-7.5 AU/mL) compared to non-transplanted, uninfected naïve subjects (14209 AU/mL, 95% CI: 11261-18836 AU/mL) (p<0.0001). In LT patients, Moderna-evoked seropositivity trend was higher by 23-fold than Pfizer. 2D COVID-19 vaccination elicits a dampened serological response in LT patients. Whether assessing other arms of host immunity combined with higher vaccine dose can better capture and elicit improved immunogenicity in this immunocompromised population warrants investigation.

Competing Interest Statement

Abbott Diagnostics provided part of the antibody testing reagents. But they did not have any role in the study design, collection, analyses, interpretation of data, drafting manuscript, or in the decision to publish the results. The authors declare no other conflict of interest.

Funding Statement

The authors received no financial support for this study.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Serum samples from LT recipients vaccinated for SARS-CoV-2 with 2D of either the Pfizer-BioNTech or Moderna vaccines or 2D-vaccinated naive (non-transplanted and COVID-19 non-exposed) group were used in this study. They were de-identified, discarded, and remnant blood samples available in the laboratory after routine analysis. This study involved no specific collection of samples. The University of Texas Southwestern Medical Center Institutional Review Board granted a waiver of consent for this study.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Due to ethical reasons, the data are not publicly available. However, upon request, the data presented in this study can be shared.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted May 05, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Serological Response in Lung Transplant Recipients after Two Doses of SARS-CoV-2 mRNA Vaccines
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Serological Response in Lung Transplant Recipients after Two Doses of SARS-CoV-2 mRNA Vaccines
Madhusudhanan Narasimhan, Lenin Mahimainathan, Andrew E. Clark, Amena Usmani, Jing Cao, Ellen Araj, Fernando Torres, Ravi Sarode, Vaidehi Kaza, Chantale Lacelle, Alagarraju Muthukumar
medRxiv 2021.04.26.21255926; doi: https://doi.org/10.1101/2021.04.26.21255926
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Serological Response in Lung Transplant Recipients after Two Doses of SARS-CoV-2 mRNA Vaccines
Madhusudhanan Narasimhan, Lenin Mahimainathan, Andrew E. Clark, Amena Usmani, Jing Cao, Ellen Araj, Fernando Torres, Ravi Sarode, Vaidehi Kaza, Chantale Lacelle, Alagarraju Muthukumar
medRxiv 2021.04.26.21255926; doi: https://doi.org/10.1101/2021.04.26.21255926

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (228)
  • Allergy and Immunology (504)
  • Anesthesia (110)
  • Cardiovascular Medicine (1238)
  • Dentistry and Oral Medicine (206)
  • Dermatology (147)
  • Emergency Medicine (282)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (531)
  • Epidemiology (10021)
  • Forensic Medicine (5)
  • Gastroenterology (499)
  • Genetic and Genomic Medicine (2453)
  • Geriatric Medicine (238)
  • Health Economics (479)
  • Health Informatics (1643)
  • Health Policy (752)
  • Health Systems and Quality Improvement (636)
  • Hematology (248)
  • HIV/AIDS (533)
  • Infectious Diseases (except HIV/AIDS) (11864)
  • Intensive Care and Critical Care Medicine (626)
  • Medical Education (252)
  • Medical Ethics (74)
  • Nephrology (268)
  • Neurology (2280)
  • Nursing (139)
  • Nutrition (352)
  • Obstetrics and Gynecology (454)
  • Occupational and Environmental Health (536)
  • Oncology (1245)
  • Ophthalmology (377)
  • Orthopedics (134)
  • Otolaryngology (226)
  • Pain Medicine (157)
  • Palliative Medicine (50)
  • Pathology (324)
  • Pediatrics (730)
  • Pharmacology and Therapeutics (313)
  • Primary Care Research (282)
  • Psychiatry and Clinical Psychology (2280)
  • Public and Global Health (4833)
  • Radiology and Imaging (837)
  • Rehabilitation Medicine and Physical Therapy (491)
  • Respiratory Medicine (651)
  • Rheumatology (285)
  • Sexual and Reproductive Health (238)
  • Sports Medicine (227)
  • Surgery (267)
  • Toxicology (44)
  • Transplantation (125)
  • Urology (99)